Skip to main content

Table 2 Demographic parameters, comorbidities, pulmonary involvement and symptoms at admission

From: A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D—a randomised multicentre international clinical trial

 

Cholecalciferol group

Control group

n

n=274

n

n=269

Demographics

 Age (years), median [IQR]

274

59.0 [49.0, 70.0]

269

57.0 [45.0, 67.0]

 Males, n (%)

274

181 (66.1)

269

172 (63.9)

 BMI (Kg/m2), median [IQR]

214

28.3 [25.7, 30.9]

207

28.7 [25.9, 32.4]

 Smokers, n (%)

272

31 (11.4)

269

29 (10.8)

Comorbidities

 Hypertension, n (%)

274

114 (41.6)

269

124 (46.1)

 Diabetes, n (%)

274

58 (21.2)

269

76 (28.3)

 Cardiovascular disease, n (%)

274

55 (20.1)

269

60 (22.3)

 Asthma, n (%)

274

14 (5.1)

269

16 (5.9)

 COPD, n (%)

274

14 (5.1)

269

9 (3.3)

Pulmonary involvement, n (%)a

274

234 (85.4)

269

217 (80.7)

Symptoms

 Fever, n (%)

274

190 (69.3)

269

198 (73.6)

 Cough, n (%)

274

185 (67.5)

269

176 (65.4)

 Weakness, n (%)

274

167 (60.9)

269

171 (63.6)

 Dyspnoea, n (%)

274

150 (54.7)

269

143 (53.2)

 Headache, n (%)

274

93 (33.9)

269

95 (35.3)

 Anosmia, n (%)

274

46 (16.8)

269

61 (22.7)

 Diarrhoea, n (%)

274

45 (16.4)

269

60 (22.3)

 Ageusia, n (%)

274

37 (13.5)

269

40 (14.9)

 Other, n (%)

274

52 (19.0)

269

57 (21.2)

 Number of symptoms, median [IQR]

274

3.0 [2.0, 5.0]

269

4.0 [2.0, 5.0]

  1. n number of patients available for analysis, IQR interquartile range, COPD chronic obstructive pulmonary disease
  2. aAssessed by chest X-ray and/or computed axial tomography